1. Evaluation of disease-free survival (DFS) as a surrogate for overall survival (OS) in the adjuvant therapy of HER2-positive early breast cancer (EBC) calls for individual-patient data (IPD). (March 2017) Authors: Saad, E.; Delaloge, S.; Mavroudis, D.; Perez, E.; Piccart-Gebhart, M.; Schneider, B.; Wolmark, N.; Buyse, M.; Burzykowski, T. Journal: Breast Issue: Volume 32(2017)Supplement 1 Page Start: S26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Genetic evaluation based on family history and Her2 status correctly identifies TP53 mutations in very early onset breast cancer cases. (29th April 2014) Authors: Fostira, F.; Konstantopoulou, I.; Mavroudis, D.; Tryfonopoulos, D.; Yannoukakos, D.; Voutsinas, G.E. Journal: Clinical genetics Issue: Volume 87:Number 4(2015:Apr.) Page Start: 383 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PO-40: Therapeutic approaches of superior vena cava syndrome in patients with non-small cell lung cancer (NSCLC). Issue 213 (May 2022) Authors: Dimakakos, E.; Grammoustianou, M.; Sarropoulou, F.; Kouvela, M.; Gkiozos, I.; Kotteas, E.; Gerotziafas, G.; Mavroudis, D.; Syrigos, K.N. Journal: Thrombosis research Issue: Issue 213(2022)Supplement 2 Page Start: S29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PO-45: Cancer-associated thrombosis (CAT) in gynecological cancers: data from ACT4CAT study. Issue 213 (May 2022) Authors: Tsoukalas, N.; Christopoulou, A.; Timotheadou, E.; Athanasiadis, I.; Koumarianou, A.; Peroukidis, S.; Samelis, G.; Psyrri, A.; Kapodistrias, N.; Nikolakopoulos, A.; Andreadis, C.; Ardavanis, A.; Samantas, E.; Papandreou, C.; Mavroudis, D.; Bokas, A.; Barbounis, V.; Kentepozidis, N.; Athanasiadis,... Journal: Thrombosis research Issue: Issue 213(2022)Supplement 2 Page Start: S32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG). Issue 1 (April 2015) Authors: Kotsakis, A.; Kentepozidis, N.; Emmanouilidis, Ch.; Polyzos, A.; Agelidou, A.; Vaslamatzis, M.; Chandrinos, V.; Agelaki, S.; Vamvakas, L.; Kalbakis, K.; Katsaounis, P.; Stoltidis, D.; Nintos, G.; Hatzidaki, D.; Vetsika, E.K.; Mavroudis, D.; Georgoulias, V. Journal: Lung cancer Issue: Volume 88:Issue 1(2015:Apr.) Page Start: 57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG). Issue 1 (April 2015) Authors: Kotsakis, A.; Kentepozidis, N.; Emmanouilidis, Ch.; Polyzos, A.; Agelidou, A.; Vaslamatzis, M.; Chandrinos, V.; Agelaki, S.; Vamvakas, L.; Kalbakis, K.; Katsaounis, P.; Stoltidis, D.; Nintos, G.; Hatzidaki, D.; Vetsika, E.K.; Mavroudis, D.; Georgoulias, V. Journal: Lung cancer Issue: Volume 88:Issue 1(2015:Apr.) Page Start: 57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗